Aiosyn

Nijmegen, Netherlands

Aiosyn employs deep learning models to discern between normal and abnormal tissue patterns with unprecedented accuracy, accelerating and improving clinical workflow. They provide several solutions for clinical diagnostics that reduce workflow inefficiencies by streamlining the process of pathological examination, improving its overall quality, and reducing its cost. Current products offered by Aiosyn focus on breast and prostate cancer diagnosis, and they are expanding to applications involving colorectal, lung and kidney tissue. Additionally, they have designed specific solutions for the Life Sciences industry in order to identify novel pathology-based biomarkers that can accelerate drug development. Aiosyn offers a highly interoperable platform (cloud or on-premise), with a focus on ISO-13485 certification, competitively priced, and ready to accommodate any size of workload at global scale.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Aiosyn on @MedStartr Today #Pathology #AIML #Diagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/WB5l6EqxKmI

Get Involved in Aiosyn

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2021
Website: www.aiosyn.com/

Disease Areas

Pathology

Technologies

Deep LearningAI AlgorithmsDigital Pathology

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Aiosyn?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.